KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline KalVista Pharmaceuticals, Inc. today announced that the newly published International Guideline on the Diagnosis and Management of Pediatric Patients…
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been dosed in a Phase 1 clinical…
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi…
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug…
Regional Dermatology Joins Epiphany Dermatology Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in Missouri through its partnership with Regional Dermatology, LLC. Founded in 2010 by Sarah Jensen, M.D.,…
Corazon and Columbia HeartSource Announce Partnership Offering First-of-its-Kind Open-Heart Surgery Accreditation Columbia HeartSource, an extension of Columbia University Irving Medical Center’s Department of Surgery and Division of Cardiology and Corazon, a national leader in strategic program development for cardiovascular services, today…
Atlas Oncology Partners Raises $28M Series A to Scale Value-Based Oncology Care Atlas Oncology Partners today announced the closing of its Series A financing. Atlas was founded by Rubicon Founders, a healthcare investment firm focused on building and growing companies…
NashBio Announces Key Leadership Roles, Advancing Technological Enablement and Access to Real-World Data Nashville Biosciences LLC a leading real-world, multi-omics data company, today announced the appointment of Wacey Richards to Chief Technology Officer (CTO) and Elizabeth Ann Stringer to Chief…
HemoSonics’ Quantra Hemostasis System for Obstetric Procedures Named a 2026 Edison Awards Finalist HemoSonics LLC, a medical device company focused on acute bleeding management, today announced that its Quantra® Hemostasis System for Obstetric Procedures is one of the top three finalists in the Women’s…
NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors NextPoint Therapeutics, a clinical-stage biotechnology company developing a new world of precision therapeutics through its leading scientific work on the novel B7-H7 axis,…
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma Nuvation Bio Inc. a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced finalization of a protocol amendment to…
Ethris and German Center for Infection Research (DZIF) Announce Strategic Collaboration to Develop mRNA-Based Vaccines Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and the German Center for Infection Research (Deutsches Zentrum für Infektionsforschung, DZIF), today announced…
